Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor

Author(s): Ugo De Giorgi, Alberto Pupi, Gina Turrisi, Iolanda Montenora, Stefano Morini, Mozghan Fayyaz, Michele De Simone, Giammaria Fiorentini.

Journal Name: Reviews on Recent Clinical Trials

Volume 2 , Issue 1 , 2007

Become EABM
Become Reviewer


The extraordinary success of imatinib in gastrointestinal stromal tumor (GIST) represents a model for molecularly targeted therapy of solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. For the optimal management of the patients treated, a multidisciplinary approach, including medical oncologists, surgeons, pathologists, and radiologists is needed. In this article, we reviewed recent advances in the clinical management of GIST patients treated with imatinib, and in the knowledge of the molecular mechanisms that are basic to imatinib effects.

Keywords: Imatinib, KIT, Gastrointestinal stromal tumor, GIST, Imaging

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [43 - 48]
Pages: 6
DOI: 10.2174/157488707779318143

Article Metrics

PDF: 9